B7-H4 expression in human infiltrating ductal carcinoma-associated macrophages

LEI LIU1,2, DALIN LI3, SHUANG CHEN1, RAN ZHAO4, DA PANG3, DIANJUN LI1 and ZHENKUN FU1

1Department of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Heilongjiang Academy of Medical Sciences; 2College of Bioinformatics Science and Technology, Harbin Medical University; 3Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University; 4Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China

Received June 30, 2015; Accepted July 6, 2016

DOI: 10.3892/mmr.2016.5510

Abstract. B7-H4 is a co-inhibitory molecule of the B7 family, which is expressed on antigen-presenting cells (APCs) and is able to limit the T-cell immune response. Macrophages act as professional APCs and are important for immunoregulation of the tumor microenvironment in breast cancer. In order to identify the association between the presence of B7-H4 on macrophages and infiltrating ductal carcinoma (IDC), the present study investigated the expression of B7-H4 on macrophages with different polarizations. The expression levels of B7-H4 in IDC tissues were determined using immunohistochemistry, and the expression of B7-H4 on macrophages in the breast IDC microenvironment were determined using western blot analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The expression levels of interleukin (IL)-6 and IL-10 were detected in IDC tissues and the supernatants of polarized macrophages using an enzyme-linked immunosorbent assay and RT-qPCR. The present study demonstrated that B7-H4 was overexpressed in IDC tissues and macrophages. In vitro, M1 and M2 macrophages exhibited different expression levels of B7-H4. IL-6 and -10 exhibited higher expression in the IDC tissues compared with in distal pericarcinomatous tissues. In conclusion, B7-H4 exhibited overexpression in IDC tissues and cultured macrophage cells. Furthermore, M2 macrophages exhibited higher expression levels of B7-H4 compared with the M1 subtype. In addition, IL-6 and -10 may be associated with B7-H4 expression on macrophages of different polarizations in the IDC microenvironment.

Introduction

Infiltrating ductal carcinoma (IDC) is one of the most common malignant tumors in female breast cancer (1). Tumor-specific immune promoting and inhibiting responses are important for the pathogenesis of IDC (2). CD4+ regulatory T cells at tumor sites may significantly suppress immune responses, leading to immune tolerance of breast cancer cells (3). Conversely, CD8+ T cells may lead to an antitumor response against neoplastic cells (4). A recent study suggested that the plasticity of tumor-infiltrated T-cell subsets was influenced by several factors, including the tumor microenvironment and antigen-presenting cells (APCs) (5). APCs, such as macrophages, may regulate the differentiation of T cells via co-stimulatory/inhibitory molecules expressed on the surface of cells and soluble products, including various cytokines, such as interleukin (IL)-10 and -6. Based on the polarization of type 1 and type 2 T helper cells (Th1 and Th2), macrophages may be divided into the classically activated (M1) macrophage phenotype and the alternatively activated (M2) macrophage phenotype (6,7). M1 macrophages promote the antitumor response of T cells, and M2 macrophages promote regulatory immune responses and enhance tumor growth. However, the exact function of tumor-infiltrated macrophages in the progression of IDC remains to be elucidated (8-10).

B7 co-stimulatory/inhibitory family molecules are expressed by macrophages and tumor cells, and are important regulators of the balance between antitumor and tumor-promoting immune responses. CD80/86 promotes interferon-γ (IFN-γ) expression, which in turn mediates the Th1 response, and are frequently expressed by M1 macrophages. Programmed death-ligand 1 (PD-L1)/L2 and B7-H4 reduce T-cell responses and are expressed by M2 macrophages.
B7-H4, also termed B7x and B7S1, is a co-inhibitory molecule for T-cell activation signaling. Due to this function, B7-H4 may limit the proliferation, cytokine secretion and the development of cytotoxicity of T cells, including CD4+ and CD8+ T cells (11,12). The expression of the co-inhibitory molecule B7-H4 in cancer cells may be associated with tumor progression, due to its importance in the tumor microenvironment and its significance in the activation of T cells. The present study demonstrated that B7-H4 may be overexpressed in the breast IDC microenvironment, and tumor-infiltrated macrophages may also express B7-H4. However, the factor that induces B7-H4 expression in macrophages remains to be elucidated. It is possible that specific cytokines in the breast IDC microenvironment may be associated with B7-H4 expression in macrophages.

The present study characterized B7-H4 expression in tumor-infiltrated macrophages in situ. In addition, in vitro experiments revealed that macrophages of different polarizations may express various levels of B7-H4. In congruence with this, the M1 distinctive cytokine IL-6 and the M2 distinctive cytokine IL-10 (13) were increased in the IDC microenvironment when compared with pericarcinomatous (PC) tissue. Furthermore, different expression levels of IL-6 and -10 were detected in M1 and M2 phenotype cell cultures. The present study revealed the association between B7-H4 and specialized subpopulations of macrophages, along with the potential influence B7-H4 expression may have in the IDC microenvironment.

Materials and methods

Human tissue biopsies. Paired IDC and PC tissues were collected from 61 patients with IDC were obtained from Outdo BioTech Co., Ltd. (Shanghai, China). In addition, six frozen IDC samples from breast cancer surgery between 2008 and 2012 were obtained from the tissue bank in the Third Affiliated Hospital of Harbin Medical University (Harbin, China) for immunofluorescence. The patients had a clear pathological diagnosis according to the American Joint Committee on Cancer (AJCC) staging system. The present study was approved by the ethics committee of the Third Affiliated Hospital of Harbin Medical University and all patients provided written informed consent. In addition, the expression levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were detected in 31 patients. For paraffin-embedded sections of IDC and PC samples, the reagents for detection of ER, PR and HER2 were obtained from Maixin Biotech Co., Ltd (Fuzhou, China). For paraffin-embedded breast IDC and PC tissue samples were prepared by Outdo BioTech Co., Ltd., they were sectioned (4 μm) using a Leica RM2245 microtome (Leica Microsystems, Wetzlar, Germany). The samples were stained with rabbit anti-B7-H4 monoclonal primary immunoglobulin (Ig)G antibody (1:300, GeneTex, Irvine, CA, USA; cat. no. GTX42699) overnight at 4°C with agitation, followed by ImmunoCruz rabbit LSAB Staining system (Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-2051). Subsequently, images were obtained using Nikon Eclipse 80i microscope (Nikon Corporation, Tokyo, Japan).

IHC scoring was performed on the 61 paired IDC and PC samples from patients with IDC (14). Proportion and intensity scores were calculated for each sample. The intensity of immunostaining was scored by visual assessment of the intensity (brown color) in positively stained cells: 0, none; 1, weak; 2, intermediate and 3, strong. The proportion score represented the percentage of positively stained cells in the entire tissue section: 0, none; 1, <5%; 2, 5-25%; 3, 26-50%; 4, 51-75% and 5, >75%. Overall B7-H4 expression in the IDC and PC samples was expressed as a histoscore, which was the sum of the proportion (0-5) and the intensity scores (0-3), producing a range between 0-8, with a maximum possible score of 8.

Immunochemistry (IHC) and scoring. The paraffin-embedded breast IDC and PC tissue samples were prepared by Outdo BioTech Co., Ltd., they were sectioned (4 μm) using a Leica RM2245 microtome (Leica Microsystems, Wetzlar, Germany). The samples were stained with rabbit anti-B7-H4 monoclonal primary immunoglobulin (Ig)G antibody (1:300, GeneTex, Inc., Irvine, CA, USA; cat. no. GTX42699) overnight at 4°C with agitation, followed by ImmunoCruz rabbit LSAB Staining system (Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-2051). Subsequently, images were obtained using Nikon Eclipse 80i microscope (Nikon Corporation, Tokyo, Japan).

IHC scoring was performed on the 61 paired IDC and PC samples from patients with IDC (14). Proportion and intensity scores were calculated for each sample. The intensity of immunostaining was scored by visual assessment of the intensity (brown color) in positively stained cells: 0, none; 1, weak; 2, intermediate and 3, strong. The proportion score represented the percentage of positively stained cells in the entire tissue section: 0, none; 1, <5%; 2, 5-25%; 3, 26-50%; 4, 51-75% and 5, >75%. Overall B7-H4 expression in the IDC and PC samples was expressed as a histoscore, which was the sum of the proportion (0-5) and the intensity scores (0-3), producing a range between 0-8, with a maximum possible score of 8.

Immunochemistry. Frozen breast IDC and PC tissue samples were sectioned using a Microm HM525 freezing microtome (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The specimens were stained with primary antibodies overnight at 4°C, as follows: Rabbit anti-B7-H4 polyclonal...
primary IgG antibody (1:200, Santa Cruz Biotechnology, Inc.; cat. no. 68872), mouse anti-CD68 monoclonal IgG antibody (1:200, Santa Cruz Biotechnology, Inc.; cat. no. 20060), rabbit anti-CD163 polyclonal primary IgG antibody (1:200; Abcam, Cambridge, UK; cat. no. ab87099), followed by Alexa Fluor 488-conjugated donkey anti-mouse IgG and Alexa Fluor 555-conjugated donkey anti-rabbit IgG (1:200; Abcam; cat. no. ab150105) for 1 h at 37°C in the dark. The DAPI solution (1 µg/ml; Solarbio Science & Technology Co., Ltd., Beijing, China) was used for nuclear staining. The images were obtained using a Nikon Eclipse 80i fluorescence microscope.

Western blot analysis. The macrophages obtained from PBMCs and Thp1 cells were resuspended in lysis buffer and 2 mM phenylmethane sulfonyl fluoride (Solarbio Science & Technology Co., Ltd.). Lysates were centrifuged at 12,000 x g for 5 min at 4°C. The protein concentration was quantified by BCA Protein Assay kit (Solarbio Science & Technology Co., Ltd.) and 40 µg was loaded into 12% SDS-PAGE gels. The proteins were transferred to nitrocellulose membranes. Subsequently, the expression levels of B7-H4 were detected by immunoblotting using β-actin as a housekeeping protein. The membranes were blocked with 5% skim milk at room temperature for 1 h. The primary antibodies used were polyclonal rabbit anti-B7-H4 IgG antibody (1:300; Santa Cruz Biotechnology, Inc.; cat. no. sc-68872) and mouse anti-β-actin monoclonal antibody (1:4,000; ProteinTech Group, Inc., Chicago, IL, USA; cat. no. 66009-1) at 4°C overnight. The secondary antibodies used were horseradish peroxidase (HRP)-conjugated affinity pure goat anti-rabbit (1:2,000; cat. no. SA00001-1) and anti-mouse IgG (1:2,000; ProteinTech Group, Inc.; cat. no. SA00001-2) at 37°C for 1 h. The Luminata Forte Western HRP substrate (EMD Millipore, Billerica, MA, USA) was used for enhanced chemiluminescence visualization. Finally, the rabbit anti-human B7-H4 monoclonal primary IgG antibody (1:300, GeneTex, Inc.) was used as a repeated verification test. The western blots were analyzed using ImageJ 1.48 software (imagej.nih.gov).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RNA was extracted from macrophages obtained from PBMCs and Thp1 cells using TRizol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.) was used for mRNA RT. The RT was conducted as follows: 25°C for 10 min; 37°C for 2 h; 85°C for 5 min; and then paused at 12°C. The primer sequences used for RT-qPCR were as follows: B7-H4, forward (F) 5'-TCTGGGCAATCCC AAGTTGAC-3' and reverse (R) 5'-TCCGGCTTTTGATCT CCGAT-3'; IL-6, F 5'-ACTCACTCTTTACGAACGAT TG-3' and R 5'-CCATCTTGTGGAAGGTTCAGTTG-3'; and IL-10, F 5'-GACTTTAAGGTTACCCGTTG-3' and R 5'-TCACATGCGCTTGATGTCTG-3'. The primer sequences for the control, glyceraldehyde 3-phosphate dehydrogenase, were as follows: F 5'-CAAGTTCACGGGCAC AGTCAA-3' and R 5'-GGTGTCATGACGGCCTTCA-3'. The primers were obtained from Invitrogen (Thermo Fisher Scientific, Inc.). The reaction was performed using ABI Power SYBR Green PCR Master mix on a ABI StepOne Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 95°C for 10 min; 40 cycles of 95°C for 20 sec and 60°C for 30 sec. The results were quantified and analyzed using a Cq method (15,16) and melting curve analysis.

Flow cytometry. The present study determined the purity of monocytes from PBMCs using mouse fluorescein isothiocyanate-conjugated anti-IgG CD14 (1 µg/test; cat. no. 11-0141-81). The M1 phenotype was verified using mouse phycoerythrin-conjugated anti-CD86 IgG (0.5 µg/test; cat. no. 12-0861-81) and M2 cells were verified by mouse APC-conjugated anti-CD163 (0.5 µg/test; cat. no. 17-1639-41). All of the fluorescent-labeled antibodies were obtained from eBioscience, Inc. (San Diego, CA, USA) and incubated with cells for 20 min at 4°C and an Accuri C6 flow cytometer was used (BD Biosciences, Franklin Lakes, NJ, USA).

Statistical analysis. IHC scores were reported as the mean ± standard error of the mean. Mann-Whitney U test was used to analyze the differences in the expression of B7-H4 between IDC and PC tissues, χ² test was used to estimate the frequency of B7-H4 expression. The results of ELISA, western blotting and RT-qPCR were analyzed using Student’s t-test. All statistical analyses were performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Table I. Clinical characteristics of patients with IDC and the association between B7-H4 expression in IDC and PC tissues.

<table>
<thead>
<tr>
<th>Variable</th>
<th>IDC</th>
<th>PC</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical staging&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>5</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>II</td>
<td>31</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>III</td>
<td>14</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>ER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>19</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>-</td>
<td>12</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>PR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>15</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>-</td>
<td>16</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>HER2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>12</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>-</td>
<td>19</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.28±7.79</td>
<td>4.75±2.08</td>
<td>0.011&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>B7-H4 expression&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.10±0.78</td>
<td>4.75±2.08</td>
<td>N/A</td>
</tr>
</tbody>
</table>

IDC, infiltrating ductal carcinoma; PC, pericarcinomatous; +, positive; -, negative; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; IHC, immunohistochemistry.

<sup>a</sup>ICD tissues, n=61. Clinical staging, n=50. ER, PR and HER2 expression, n=31. The mean IHC scores ± standard error of the mean were calculated for B7-H4 expression in IDC and PC tissues. <sup>b</sup>According to the American Joint Committee on Cancer. <sup>c</sup>IHC scoring.
Results

Breast IDC tissues and tumor-associated macrophages over-express B7-H4. The expression levels of B7-H4 in breast IDC were characterized in situ. A cohort of 61 patients with IDC was selected (mean age, 53.28±7.79 years). Table I summarizes the clinical characteristics of the cohort. Paraffin-embbedded sections of IDC and PC samples were stained with a B7-H4 antibody. IHC scores were calculated and used to determine B7-H4 expression. B7-H4 had a higher expression level in the IDC tissues compared with the PC tissues (P=0.011; Fig. 1A and B and Table I). The positive rate of B7-H4 expression was also significantly higher in the tumor environment compared with the pericarcinomatous tissue as determined by \( \chi^2 \) analysis (P<0.01; data not shown). No significant difference was identified between B7-H4 expression levels and AJCC staging in patients with IDC (P>0.05). In addition, the expression levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) were detected in 31 patients. There was a significant difference in B7-H4 expression between IDC and PC tissues in ER-, PR- and HER2-positive and negative patients (P<0.05; Table II). However, when examining IDC tissues alone, no significant difference in B7-H4 expression was identified between ER-, PR- and HER2-positive and negative patients (P>0.05; Table II).

Immunofluorescence analysis detected B7-H4 expression in IDC tissue. B7-H4 was shown to be expressed on the surface of macrophages, which were CD68+; therefore, it is possible that B7-H4 was not solely expressed on the surface of breast cancer cells but also on macrophages in the breast IDC microenvironment (Fig. 1C).

M0, M1 and M2 cells express various levels of B7-H4. The CD14+ monocytes from PBMC were assessed for purity in the present study, and the proportion of CD14+ cells was >97% (data not shown). Distinctive surface markers were also highly expressed on macrophages; CD86 was highly expressed on M1 cells and CD163 was highly expressed on M2 cells (Fig. 2A).

Western blot analysis demonstrated that the expression levels of B7-H4 were significantly higher in M2 cells compared...
Table II. Association between clinical characteristics of breast IDC and B7-H4 expression (n=31).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Expression</th>
<th>IDC</th>
<th>PC</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER</td>
<td>+</td>
<td>7.05±0.90</td>
<td>5.00±1.79</td>
<td>0.002*</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>7.08±0.92</td>
<td>5.00±1.83</td>
<td>0.020*</td>
</tr>
<tr>
<td>PR</td>
<td>+</td>
<td>6.93±0.87</td>
<td>4.93±1.70</td>
<td>0.005*</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>7.19±0.91</td>
<td>5.06±1.94</td>
<td>0.006*</td>
</tr>
<tr>
<td>HER2</td>
<td>+</td>
<td>6.92±0.94</td>
<td>4.75±2.38</td>
<td>0.045*</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>7.16±0.89</td>
<td>5.16±1.55</td>
<td>0.001*</td>
</tr>
</tbody>
</table>

Mean IHC score values ± standard error of the mean were calculated for B7-H4 expression in breast IDC and pericarcinomatous tissues. Statistical differences were calculated using the Mann-Whitney U test. *P<0.05 IDC vs. PC tissues. #P>0.05 + vs. - expression levels of ER, PR or HER2. IDC, infiltrating ductal carcinoma; PC, pericarcinomatous; +, positive; -, negative; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.

Figure 2. Polarization of macrophages and expression of B7-H4 in various macrophage subtypes. (A) Analysis of the surface markers of M1 and M2 cells using flow cytometry. M1 cells expressed CD86 and M2 cells expressed CD163. (B) Western blot analysis revealed that M2 cells expressed more B7-H4 compared with M1 cells. (C) Macrophages (M1 and M2) were observed to express B7-H4 by immunofluorescence (in red; magnification, x400). (D) M2 cells exhibited higher mRNA expression levels of B7-H4 compared with M1 cells. *P<0.05. Three independent experiments were performed, data are presented as the mean ± standard error of the mean. DAPI, 4',6-diamidino-2-phenylindole.
with in M1 cells, in human monocytes and Thp1 cells (P<0.05; Fig. 2B). The verification of the western blot analysis, using a B7-H4 antibody from a different supplier, confirmed this result (data not shown).

Immunofluorescence analysis confirmed that M1 and M2 macrophages expressed B7-H4 (Fig. 2C). B7-H4 expression differed on the surface of M0, M1 and M2 cells, as detected by flow cytometry. RT-qPCR analysis revealed that B7-H4 expression was higher in M2 cells compared with in M1 cells (P<0.05; Fig. 2D).

**IL-6 and -10 are highly expressed in IDC tissues.** The present study demonstrated that IL-6 and -10 levels were significantly higher in the IDC tissues when compared with the PC tissues (P=0.006 and P=0.031; Fig. 3A). There was a significant difference in the average concentrations of IL-6 (18.72±5.69 vs. 5.80±2.96 pg/ml; P=0.006) and IL-10 (27.39±3.87 vs. 11.64±1.77 pg/ml; P=0.031) between IDC and PC tissues. These results suggest that the levels of IL-6 and -10 were three-fold higher in IDC tissues compared with in PC tissues.

*High expression levels of IL-6 in the M1 phenotype and IL-10 in the M2 phenotype.* The levels of IL-6 and -10 in M1 and M2 macrophages obtained from human Thp1 cells and PBMC CD14+ monocytes were determined using reverse transcription-quantitative polymerase chain reaction. *P<0.05, **P<0.01, ***P<0.001. Three independent experiments were performed and data is presented as the mean ± standard error of the mean. IDC, infiltrating ductal carcinoma; PC, pericarcinomatous; IL, interleukin; ELISA, enzyme-linked immunosorbent assay.
IL-10 as one for M2 cells (13), the obtained results fulfilled the expectation of polarization in macrophages.

The RT-qPCR analysis also revealed that the mRNA expression levels of IL-6 were significantly higher in the M1 phenotype when compared with the M2 phenotype (P<0.05; Fig. 3D). The mRNA expression levels of IL-10 were significantly higher in the M2 phenotype compared with the M1 phenotype (P<0.01, Fig. 3D). These results were similar to the results of the ELISA analysis.

Discussion

Macrophages are important for tumorigenesis due to their secretion of specific cytokines and proteases (17,18). The polarization of macrophages may also affect the progression and metastasis of cancer, including breast cancer (19-22). A previous study functionally classified macrophages into M1 and M2 phenotypes (23). M1 cells, which express CD86 and major histocompatibility complex II, are capable of secreting IL-6 and nitric oxide synthases. However, M2 cells, which express CD163, secrete IL-10 and transforming growth factor-β (TGF-β). According to a previous study, macrophages may be stimulated by IL-10, IL-4 and TGF-β in the tumor microenvironment in order to induce the M2 phenotype (13). Due to the characteristics of macrophages in the tumor microenvironment, overexpression of the suppressive co-stimulatory molecule B7-H4 is a possibility. As a member of the B7 family, B7-H4 has an inhibitory effect on cellular immune responses. Therefore, B7-H4 should be highly expressed in the tumor microenvironment, which is under a state of immune suppression. Previous studies have detected high B7-H4 expression levels in various tumors, including ovarian, lung and breast cancer (24-28). Furthermore, a previous study demonstrated that B7-H4-expressing macrophages were significantly higher in peripheral blood from patients with cancer compared with those from healthy donors (25). Cytokines in peripheral blood may be the induction factors for B7-H4-expressing macrophages in patients with cancer. Therefore, the present study selected human monocytes from peripheral blood and the Thp1 monocyte cell line as targets. The macrophages were stimulated into two different polarization types in vitro. As determined by the detection of surface markers and cytokine secretion, the polarization of macrophages was successful in the present study.

In the tumor microenvironment, M1 cells may limit the development and progression of tumors. Conversely, M2 cells are able to induce tumor promotion (29,30). Due to the inhibitory function of B7-H4, it was hypothesized that M2 macrophages would express higher levels of B7-H4 compared with M1 cells. In the present study, both M1 and M2 human macrophages expressed B7-H4; however, compared with M1 cells, M2 cells exhibited significantly higher levels of B7-H4.

The high expression of B7-H4 in IDC tissues may be due to specific cytokines. Therefore, the present study investigated the levels of IL-6 and -10, and demonstrated that they were higher in IDC tissues compared with PC tissues. This has also been observed in ovarian cancer research, which has revealed that IL-6 and -10 induced B7-H4 expression in macrophages (23). Different concentrations and mRNA expression levels of IL-6 and -10 were observed in the M1 and M2 cells in the present study. Future research will aim to determine the source of IL-6 and -10 in the breast cancer microenvironment, and the association between the expression levels of IL-6 and -10 and B7-H4 expression in macrophages of different polarization states. IL-6 and -10 may stimulate signal transducer and activator of transcription 3 (Stat3) via the janus kinase/Stat signaling pathway (31,32). Therefore, IL-6 and -10 may be regulated with B7-H4, and the association between B7-H4 and IL-6 or IL-10 signaling regulation should be investigated in future studies.

As a co-inhibitory molecule, B7-H4 has the ability to regulate the immune response in the tumor microenvironment. In addition, B7-H4, as a negative stimulatory molecule, has an inhibitory capacity for activation of the immune response, contrary to the combination of B7-CD28 (33). Therefore, B7-H4 may be a potential target for immunotherapy in various tumors, including breast cancer (34).

In conclusion, the present study indicated that B7-H4 may be overexpressed on the majority of cells in the IDC microenvironment, including macrophages. In vitro experiments revealed that M1 and M2 cells expressed B7-H4. Compared with M1 cells, M2 cells exhibited significantly higher expression levels of B7-H4. In addition, the expression levels of IL-6 and -10 were higher in human breast IDC tissues compared with breast distal PC tissues, and various levels of IL-6 and -10 were observed in the M1 and M2 macrophages.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 81201594), the China Postdoctoral Science Foundation funded project (grant no. 2012M520036) and the Postdoctoral Science Foundation of Heilongjiang Province China (grant no. LRB 2011300).

References